Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Breathalyzer for diabetes? new study sniffs out blood sugar clues.

NCT ID NCT07147010

Knowledge-focused Sponsor: DCB Research AG Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether chemicals in the breath (VOCs) match blood sugar levels in people with type 2 diabetes. Twenty adults with diabetes had their breath and blood sugar measured after drinking sugar water and receiving insulin. The goal was to see if a breath test could one day replace finger pricks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Oct 2024

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed written informed consent * T2D treated with one or more oral anti-diabetic drugs (incl GLP-1 and/or GIP) * \< 10 years since T2D diagnosis * HbA1c ≤8% (HbA1c based on last measurement by treating physician but not older than 120 days) * Willingness to undergo study procedures * Age 45 -70 years (inclusive) Exclusion Criteria: * Pregnancy and/or lactation period * Currently on chronic or occasional treatment with pulmonary drugs * Insulin dependency * Smoking (last cigarette within the last six months) * BMI above 30 kg/m² * Lp(a) above 125 nmol/l * LDL not in the individual target range of an earlier cholesterol goal according ESC guideline 2021 (LDL based on last measurement by treating physician but not older than 30 days) * Irregular 12-lead ECG or increased carotid plaque burden based on a three-point sonography. Both examinations are performed and evaluated according to the investigator's judgment. * History of, or manifested, cardiovascular diseases * Medical history of epilepsy or other neurological disease associated with seizure events * Known sensitivity to medical grade adhesives * Comorbidities that are suspected to alter the VOC spectra * Participation in another investigation with an investigational drug within the 30 days preceding and during the present investigation * Not able to understand, write or read German

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hyperglycemia hypoglycemia type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes

Contacts and locations

Locations

  • Inselspital Bern

    Bern, 3010, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.